Hepatoma Registry of Integrating and Aggregating EHR (electric health record)

Hepatoma Registry of Integrating and Aggregating EHR (electric health record) - HERITAGE study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046567

Enrollment

10000

Registered

2022-01-06

Start date

2021-01-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To be eligible to participate in this study, all of the following criteria must be met. 1) Patients diagnosed with hepatocellular carcinoma (HCC) by pathological diagnosis or imaging diagnosis at an NCD-registered facility after 2010 and registered in the National Liver Cancer Follow-up Database. 2) Patients who have received drug therapy for hepatocellular carcinoma at the same institution (drug therapy refers specifically to treatment with sorafenib, regorafenib, lenvatinib, ramucirumab, atezolizumab + bevacizumab, cabozantinib, durvalumab+tremelimumab, durvalumab)

Exclusion criteria

Exclusion criteria: Those who have requested refusal of inclusion in the research.

Design outcomes

Primary

Measure	Time frame
Overall survival rate, progression-free survival rate, response rate	—

Secondary

Measure	Time frame
Reason for stopping treatment, cost of treatment	—

Countries

Japan

Contacts

Public ContactYoshinari Asaoka

Teikyo University School of Medicine Department of Medicine

y-asaoka@med.teikyo-u.ac.jp03-3964-1211

Outcome results